

3/23/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Ascend Laboratories, LLC is providing notice of the introduction of a new prescription drugs with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. The new products were launched on various dates that have been noted, as some were not immediately reported. As a result of a change in personnel, a review of the state price transparency reporting is being completed to bring Ascend Laboratories, LLC into compliance.

PRODUCT NAME: Rufinamide Oral Suspension 40mg 460ML (2/25/2021)

NDC: 67877-0673-62

PRODUCT NAME: Deferasirox Oral Gran 90mg- 0.155x30's (8/1/2020)

NDC: 67877-0675-84

PRODUCT NAME: Deferasirox Oral Gran 180mg- 0.320x30's (8/1/2020)

NDC: 67877-0676-84

PRODUCT NAME: Deferasirox Oral Gran 360mg- 0.620x30's (8/1/2020)

NDC: 67877-0677-84

PRODUCT NAME: Sirolimus 2mg tablets (3/23/2021)

NDC: 67877-0748-01

Sincerely,



James Giuliano - CFO